Vertex Pharmaceuticals (VRTX) Cash from Operations (2009 - 2026)

Vertex Pharmaceuticals' Cash from Operations history runs 18 years deep, the most recent figure standing at 1428100000.0 for Q1 2026.

• In Q1 2026, Cash from Operations rose 74.39% year-over-year to 1428100000.0; the TTM figure through Mar 2026 stood at 4240600000.0 (up 532.58% YoY), while the FY2025 annual figure was 3631400000.0, up 837.19% from the prior year.
• Cash from Operations for Q1 2026 stood at 1428100000.0, up from 498000000.0 in the prior quarter.
• The five-year high for Cash from Operations was 1428100000.0 in Q1 2026, with the low at 3753600000.0 in Q2 2024.
• The 5-year median for Cash from Operations is 1073100000.0 (2025), against an average of 719652941.18.
• The sharpest annual moves came in 2022 and 2024: Cash from Operations surged 670.76% in 2022, then plunged 430.89% in 2024.
• Vertex Pharmaceuticals' Cash from Operations stood at 1078400000.0 in 2022, then sank by 78.25% to 234600000.0 in 2023, then soared by 149.19% to 584600000.0 in 2024, then retreated by 14.81% to 498000000.0 in 2025, then surged by 186.77% to 1428100000.0 in 2026.
• Business Quant data shows VRTX's Cash from Operations at 1428100000.0 in Q1 2026, 498000000.0 in Q4 2025, and 1241400000.0 in Q3 2025.